The study population was deliberately targeted at one of the highest-risk human–animal interfaces in West Africa. Villages were purposively sampled to include 16 communities affected and 28 unaffected by the 2013–16 epidemic, with designations confirmed through national health databases and key informant interviews with village leaders and healthcare workers. Within each village, families known to practice wildlife hunting were approached, and the senior hunter together with a spouse or closest relative was invited to participate. In total, 511 participants were enrolled from 40 villages in 2017 and 648 from 43 villages in 2023, with just over half of the original cohort successfully resampled six years later. Wildlife hunters, all male, made up 56 percent of the study population, while the remainder reported close household contact with a hunter. Farming was the dominant occupation, and questionnaires administered in French and the local Toma language captured detailed behavioral data on hunting, butchering and consumption of wild animals.

Those behavioral data underscore how pervasive wildlife exposure is in this setting. Ninety percent of respondents in 2023 reported consuming bushmeat, and 94 percent helped handle, wash or prepare wildlife carcasses before cooking. Wildlife was consumed a median of seven days per month, and hunters pursued game a median of six days per month, with hunting generally practiced year-round. Agouti was the most frequently reported food animal, followed by rodents, antelope, boar, monkeys, pangolins and bats. Bat exposure stood out as distinctly seasonal, concentrated at the start of the dry season, and bat hunting was a specialized activity involving roughly a third of households. Contact with bats was otherwise frequent and often peridomestic, occurring around the village or inside houses two to three days per week, while cave visits were short and infrequent and guano harvesting was almost entirely absent.

Serologically, the team faced a classic analytical challenge: antibodies against one ebolavirus frequently cross-react with related species, making it difficult to distinguish genuine exposure to a specific virus from heterotypic cross-reactivity. To address this, the researchers applied an unsupervised machine-learning approach, using K-means clustering to partition individual antibody response profiles across all nine glycoprotein antigens into fifteen distinct clusters. Rather than imposing a binary seropositivity threshold for each virus — a strategy prone to misclassifying cross-reactive individuals — the clustering identified groups of people sharing similar exposure signatures. Three clusters comprising 57 individuals showed high anti-EBOV binding with cross-reactivity that declined with phylogenetic distance, a pattern consistent with prior Ebola virus exposure and closely matching profiles documented in PCR-confirmed survivors. Other clusters displayed more restricted, species-specific binding: 49 individuals against Bundibugyo virus, 13 against Taï Forest virus, and smaller groups against Reston, Měnglà and Lloviu viruses, plus a single individual reactive to Bombali virus.

To move beyond binding antibodies and assess functional immunity, the team subjected individuals from these species-specific clusters to parallel pseudotyped virus neutralization assays, in which lentiviral particles bearing filovirus glycoproteins are tested for their ability to infect cells in the presence of serially diluted serum. Among ten individuals from the Bundibugyo cluster, five showed stronger neutralization of BDBV than of Ebola virus Makona, and all five came from two villages that reported no Ebola cases during the 2013–16 epidemic. Two were marital partners from the same unaffected village, and persistent responses were documented in individuals resampled in 2023. Similarly, five of eight individuals from the Taï Forest cluster neutralized TAFV more strongly than EBOV. The convergence of binding specificity, neutralization patterns, household clustering and village-level geography led the authors to conclude that these signatures most plausibly reflect genuine exposure to viruses antigenically closer to BDBV and TAFV than to Ebola virus itself.

The spatial dimension of the findings strengthened this interpretation considerably. Village-level aggregation of antibody responses revealed marked heterogeneity, with one village — designated Village 4 and confirmed by both Ministry of Health records and informant interviews to be unaffected by the 2013–16 epidemic — showing significantly elevated mean BDBV responses in both 2017 and 2023. Some of the strongest BDBV-neutralizing individuals lived within the same household in that village. Epidemiological modeling added a behavioral correlate: consumption of nonhuman primates was associated with roughly five-fold higher odds of BDBV-cluster seropositivity in multivariable analysis, echoing the 2012 Bundibugyo outbreak in the Democratic Republic of the Congo, in which many patients reported contact with bushmeat. The geographic proximity of the Taï Forest findings to Côte d’Ivoire, site of the only documented human TAFV case following a chimpanzee necropsy, further bolstered the plausibility of local spillover.

The study also yielded a striking estimate of antibody durability. Among eleven individuals seropositive for EBOV in 2017 who were resampled in 2023, exponential decay models fitted to individual IgG trajectories produced a population-level antibody half-life of approximately 7.5 years, demonstrating that anti-EBOV antibodies persist at detectable levels a decade after the West African epidemic began. The authors caution that re-infection with subsequent antibody boosting cannot be excluded, particularly given evidence that Ebola virus circulated in the region before 2013 and that new exposures may continue. Nevertheless, the durability finding aligns with longitudinal cohort studies of Ebola survivors and has implications for serosurveillance strategies, since long-lived antibodies extend the window during which past spillover events can be detected retrospectively.

Perhaps the most novel contribution lies in the integration of satellite-derived land-cover data with the serological results. The team extracted metrics of tree cover, cropland, built area and forest fragmentation — including shape index, perimeter-area ratio and fractal dimension — at radial distances from 500 meters to 10 kilometers around each village centroid, then fitted mixed-effects logistic regression models with sampling year as a random effect. The landscape associations differed by virus in ways that hint at distinct transmission pathways. EBOV reactivity was negatively associated with tree coverage, consistent with a signature dominated by past human-to-human transmission rather than fresh zoonotic events. BDBV seroreactivity, by contrast, was positively associated with forest fragmentation within 500 meters of villages and with living in built-up areas, suggesting risk from encroachment at the forest edge. Reactivity to TAFV, LLOV and MLAV was associated with proximity to larger patches of intact forest five to ten kilometers away, a pattern the authors link to hunting deep within the forest rather than peridomestic exposure.

These environmental findings carry direct implications for prevention. If forest configuration genuinely shapes spillover risk, then conservation and landscape management could function as ecological countermeasures, protecting communities by reducing the frequency and intensity of contact between people and reservoir or amplifier hosts. The evidence base for bats as filovirus reservoirs continues to grow — Marburg and Ravn viruses have been isolated from Egyptian rousette bats, Bombali virus genomes have been recovered from free-tailed bats in neighboring Sierra Leone and from bats in Guinea, Kenya and Mozambique, and Lloviu virus has been repeatedly isolated from Schreiber’s bats in Europe — while nonhuman primates and duikers serve as susceptible intermediate or amplifier hosts. Experimental work suggesting that minimal mutations in the Bombali virus receptor-binding domain could enhance entry into human cells adds a note of caution about the spillover potential of viruses whose human pathogenicity remains unknown.

The authors are candid about the limitations inherent in serological surveillance of this kind. Targeted sampling of hunting households limits generalizability to the wider population; ubiquitous bushmeat exposure confounds species-specific risk analyses; children were excluded, leaving early-life exposure unexamined despite documented hunting practices among children elsewhere in Guinea; and historical village classifications of Ebola-affected status are vulnerable to underreporting driven by stigma and limited healthcare access, in a region with an estimated 0.2 physicians per 10,000 people. Cross-reactivity and the possibility of infection with as-yet unidentified, antigenically related filoviruses complicate interpretation, and pseudotyped assays, while necessary for biosafety, imperfectly recapitulate authentic virus neutralization. Yet the convergence of multiple independent lines of evidence — species-specific binding, differential neutralization, household and village clustering, behavioral risk factors and landscape associations — makes a compelling case that zoonotic filovirus spillover is ongoing in forested Guinea. The study’s authors argue that expanding surveillance in high-risk populations, strengthening decentralized local diagnostic capacity, and safeguarding ecosystems from further deforestation and fragmentation together offer the most promising path to intercepting the next outbreak at its source.

Subject of Research: Serological surveillance of zoonotic filovirus exposure and its environmental risk factors among wildlife hunting communities in forested Guinea

Article Title: Filovirus reactive antibodies in wildlife hunting communities suggest ongoing zoonotic spillover in forested Guinea

Article References: Hood, G., Akoi Bore, J., Tipton, T., Onivogui, Z., Sovogui, K., Zoumanigui, K. Z., Timothy, J., Roe, M., Yan, L., Scott, S., Temperton, N., Wright, E., Hughes, G., Boumbaly, S., Laing, E. D., Magassouba, N., Fornace, K., & Carroll, M. (2026). Filovirus reactive antibodies in wildlife hunting communities suggest ongoing zoonotic spillover in forested Guinea. Nature Communications, 17(1), Article 9974. https://doi.org/10.1038/s41467-026-77653-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77653-3

Keywords: filoviruses, Ebola virus, Bundibugyo virus, Taï Forest virus, zoonotic spillover, serosurveillance, wildlife hunting, bushmeat, forest fragmentation, Guinea, bats, land-use change

A comprehensive review published in the Journal of Emergency and Disaster Medicine by Sherief Musa of Cairo University’s Endemic Medicine Department synthesizes decades of research on the virus, drawing on 70 studies selected from an initial pool of 1,564 articles identified through PubMed, Web of Science, and African Journals Online, covering literature from 1968 through the end of 2025, together with guidance documents from the World Health Organization and the Centers for Disease Control and Prevention. The review arrives at a moment of genuine inflection: Marburg virus outbreaks have grown both more frequent and more geographically dispersed, with first-time occurrences reported in Guinea in 2021, Ghana in 2022, Equatorial Guinea and Tanzania in 2023, Rwanda in 2024, and now Ethiopia. The virus was first identified in 1967, when laboratory workers in Marburg and Frankfurt in Germany and in Belgrade in the former Yugoslavia fell ill after handling infected African green monkeys, Cercopithecus aethiops, imported from Uganda for pharmaceutical research. Since then, nearly twenty outbreaks have been documented, almost all in sub-Saharan Africa, ranging from isolated single cases to explosive community epidemics such as those in the Democratic Republic of the Congo in 1998 to 2000 and Angola in 2004 to 2005.

At the molecular level, Marburg virus is a non-segmented, single-stranded, negative-sense RNA virus of the family Filoviridae, a name derived from the Latin word for thread-like, a reference to the filamentous shape of viral particles. Unlike Ebola, the genus Marburgvirus contains a single species, Orthomarburgvirus marburgense, comprising two recognized variants, the Lake Victoria and Ravn viruses, whose genomes share at least 79 percent sequence homology. The viral genome spans approximately 19,000 bases and encodes seven genes arranged in a fixed order, each protein performing a specialized function in the viral life cycle. The nucleoprotein encapsidates the RNA genome into the nucleocapsid, essential for replication and transcription. Viral protein 35 acts as a polymerase cofactor while simultaneously suppressing interferon signaling, one of the body’s first lines of antiviral defense. Viral protein 40 drives the budding of new particles and further antagonizes the interferon response, and the surface glycoprotein binds host receptors to trigger internalization through endocytosis. The large protein, designated L, serves as the RNA-dependent RNA polymerase that copies the genome, and it is precisely this enzyme that several experimental antiviral drugs are designed to inhibit.

The pathogenesis of Marburg virus disease explains its devastating clinical course. After entering through mucosal surfaces or broken skin, the virus preferentially infects mononuclear phagocytic cells, including macrophages and dendritic cells. From these initial targets it spreads to regional lymph nodes and then disseminates through the bloodstream to the liver, spleen, and other lymphoid tissues, where it induces extensive necrosis. The virus suppresses the production of type I interferons and interferes with their signaling pathways, disabling innate immunity before it can mount an effective response. Dendritic cell activation is inhibited, impairing antigen presentation and leaving T-lymphocytes poorly stimulated, while inflammatory mediators drive so-called bystander apoptosis that depletes lymphocytes and hollows out adaptive immunity. Uncontrolled activation of infected macrophages then floods the circulation with pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor, producing the cytokine storm that drives vascular permeability upward and sets the stage for coagulation abnormalities.

The downstream consequences are what give the disease its hemorrhagic character. Endothelial injury, increased vascular leakage, and microvascular clotting culminate in disseminated intravascular coagulation, in which clotting factors are consumed faster than they can be replaced. Infection of hepatocytes impairs liver function and reduces the production of coagulation proteins, worsening bleeding tendencies, while infection of the adrenal cortex disrupts hormone production and destabilizes blood pressure regulation. Widespread vascular leakage depletes circulating blood volume, producing hypovolemic shock and falling perfusion to vital organs, and the terminal result is a shock-like syndrome combining vascular dysfunction, disseminated coagulopathy, and multi-organ failure. After an incubation period of 3 to 21 days, typically 5 to 10, the illness unfolds in three phases: a generalization phase of roughly five days marked by abrupt high fever around 40 degrees Celsius, severe headache, chills, myalgia, and prostration; an early organ phase from day 5 to day 13, dominated by gastrointestinal symptoms, escalating mucosal or gastrointestinal bleeding, and sometimes neurological manifestations including disorientation, agitation, seizures, and coma; and finally either recovery or a fatal outcome, typically during the second week of illness.

A recent aggregation of clinical data covering 325 patients, approximately 45 percent of all reported Marburg cases across five decades, has sharpened the clinical picture considerably. Fever proved the most consistent symptom, present in 91 percent of cases, followed by fatigue at 75 percent, headache at 64 percent, and myalgia at 47 percent. Gastrointestinal complaints were prominent, with nausea or vomiting in 66 percent of patients, diarrhea in 53 percent, and abdominal pain in 43 percent. Among hemorrhagic manifestations, hematemesis was the most frequent at 43 percent, followed by bloody diarrhea at 34 percent, bleeding gums at 23 percent, and epistaxis at 20 percent. The overall case fatality rate in that pooled analysis was 77 percent, falling to 44 percent among cases confirmed by polymerase chain reaction, and mortality across outbreaks has historically ranged from 25 to 80 percent depending on context and the quality of available medical care. Diagnosis remains difficult because early symptoms mimic malaria, typhoid fever, leptospirosis, and dengue, and hemorrhagic signs appear too late to guide early detection. Reverse transcription polymerase chain reaction testing of whole blood or plasma is the most reliable method, though a negative early sample does not exclude infection, and repeat testing is essential. Samples are extremely biohazardous and must be shipped in triple packaging for testing at biosafety level 3 or level 4 facilities, infrastructure that many African countries lack, and unlike Ebola, no field-validated rapid diagnostic test yet exists for Marburg virus.

Treatment remains the weakest pillar of the response. No licensed specific therapeutics exist, and the cornerstone of survival is intensive supportive care in designated treatment centers: intravenous fluids, vasopressors, and electrolyte correction to maintain hemodynamic stability; blood components to address hemorrhage; mechanical ventilation and renal replacement therapy for organ support; broad-spectrum antibiotics to prevent secondary bacterial infection; adequate nutrition; and psychological support. Rwanda’s 2024 outbreak demonstrated what such care can achieve, with a 77 percent survival rate that inverts historical fatality figures. Promising experimental agents are advancing through the pipeline, guided by knowledge of virus-host interactions. Small-molecule antivirals targeting the RNA-dependent RNA polymerase can impede replication, monoclonal antibodies against the viral glycoprotein have effectively neutralized the virus in preclinical studies, and phosphorodiamidate morpholino oligomers and small interfering RNAs targeting viral messenger RNAs have shown protective effects in non-human primates. Combination therapy pairing remdesivir with monoclonal antibodies was deployed during the 2024 Rwandan outbreak and reportedly improved outcomes. On the vaccine front, the World Health Organization’s Research and Development Blueprint established the Marburg Virus Vaccine Consortium to coordinate candidate development, and its technical advisory group has prioritized four viral-vectored candidates for human trials: two based on non-replicating chimpanzee adenoviruses, ChAd3 and ChAdOx1, and two on replicating vesicular stomatitis virus vectors. During the Ethiopian outbreak, the Ministry of Health reported that 2,500 doses of the cAd3-Marburg vaccine were offered to healthcare professionals and contacts of cases, echoing the experimental deployment of the ChAd3 vaccine in Rwanda in October 2024 as a real-world test of the 100-Day Mission, an initiative to develop and authorize emergency-use vaccines within 100 days of identifying an emerging pathogen.

Ethiopia’s containment of the outbreak offers lessons in adaptability. Health authorities, working with international partners, rapidly trained frontline healthcare workers, distributed critical supplies, intensified community-level monitoring, and traced contacts; as of 25 January 2026, a total of 857 contacts had been listed and had completed 21 days of follow-up. Epidemiological modeling suggests that without mitigation, Marburg virus propagates with a doubling time of 12 days in a susceptible population, but case isolation is effective if initiated no later than three days after symptom onset, underscoring the decisive value of speed. The World Health Organization declares an outbreak over 42 days, two consecutive incubation periods, after the last patient dies or tests negative and is discharged. Yet the regional risk did not vanish with Ethiopia’s declaration: the Africa Centres for Disease Control and Prevention reported suspected Marburg deaths in South Sudan in December 2025 and an alert in Wajaale, a border city in the Somaliland region, reflecting the danger of cross-border transmission along road networks connecting Ethiopia to Kenya, South Sudan, and Somalia.

The broader risk assessment is nuanced. The virus’s basic reproduction number is estimated at 1.59 with an average nine-day interval between successive cases, conditions under which large sustained epidemics are unlikely unless the virus mutates to enhance transmissibility, something experts recommend monitoring through sequence analysis of isolates from future outbreaks. A 2015 model estimated that up to 105 million people across 27 countries are vulnerable to zoonotic Marburg spillover, and the reservoir host, the Egyptian fruit bat Rousettus aegyptiacus, whose range defines the potential risk area, carries active infection in roughly 2 to 3 percent of bats at any time, with biannual seasonal pulses that coincide with heightened spillover risk. The 2014 to 2016 West African Ebola epidemic, which arose from a single spillover event and produced 28,000 cases and 11,000 deaths, stands as the cautionary precedent. Marburg virus is classified as a Category A bioterrorism agent by the CDC owing to its severity, mortality, and the absence of licensed countermeasures, adding an intentional-outbreak dimension to preparedness planning. With climate change, deforestation, mining, and urbanization expanding human-bat contact, and with the WHO and GAVI both ranking Marburg among priority pandemic threats, researchers and policymakers argue that sustained investment in diagnostics, vaccines, therapeutics, and One Health surveillance is no longer optional but essential to averting the next high-consequence filovirus crisis.

Subject of Research: Marburg virus disease epidemiology, pathogenesis, and outbreak preparedness in light of Ethiopia's first outbreak

Article Title: Marburg virus disease: the next threat in the making?

Article References: Musa, S. (2026). Marburg virus disease: the next threat in the making?. Journal of Emergency and Disaster Medicine, 2(1), Article 8. https://doi.org/10.1007/s44467-026-00011-2

Image Credits: AI Generated

DOI: 10.1007/s44467-026-00011-2

Keywords: Marburg virus, Marburg virus disease, filoviruses, hemorrhagic fever, zoonosis, Ethiopia outbreak, Rousettus aegyptiacus, vaccine development, antiviral therapeutics, outbreak preparedness, cytokine storm, global health security